Darunavir Krka

What Is Darunavir Krka and What Is It Used For?

Darunavir Krka is an antiretroviral medicine belonging to the class of protease inhibitors. It is used together with low-dose ritonavir and other HIV medicines to treat Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and children aged 3 years and older who weigh at least 15 kg.

Darunavir works by selectively blocking the HIV-1 protease enzyme, which is essential for the virus to produce mature, infectious viral particles. When the protease enzyme is inhibited, the virus can still replicate its genetic material, but the newly produced viral particles remain immature and non-infectious. This effectively halts the progression of infection and allows the patient's immune system to begin recovering.

As a second-generation protease inhibitor, darunavir was specifically designed to overcome resistance patterns that had emerged against earlier drugs in this class, such as indinavir, nelfinavir, and lopinavir. Its molecular structure allows it to bind very tightly to the active site of the protease enzyme, including many mutant forms. This gives darunavir what is known as a high genetic barrier to resistance, meaning multiple mutations are typically required before the virus develops clinically significant resistance to the drug.

Darunavir Krka is manufactured by KRKA d.d., Novo mesto, a pharmaceutical company based in Slovenia. It is a generic medicine, which means it has been demonstrated through comprehensive bioequivalence studies to deliver the same amount of active substance to the body at the same rate as the originator product. The European Medicines Agency (EMA) has approved Darunavir Krka based on these studies, confirming that it meets the same rigorous standards for quality, safety, and efficacy.

It is critical to understand that darunavir does not cure HIV infection. Patients who achieve undetectable viral loads through antiretroviral therapy still carry the virus in reservoir cells and must continue treatment indefinitely. However, effective viral suppression dramatically reduces the risk of opportunistic infections, AIDS-defining illnesses, and HIV-related mortality. Furthermore, people living with HIV who maintain an undetectable viral load cannot transmit the virus sexually, a concept known as U=U (Undetectable = Untransmittable), endorsed by major public health organisations including the WHO and UNAIDS.

What Should You Know Before Taking Darunavir Krka?

Before starting Darunavir Krka, your healthcare provider will assess your medical history, current medications, liver function, and any known allergies. There are several important contraindications, warnings, and drug interactions to be aware of.

Contraindications

Do not take Darunavir Krka if you are allergic to darunavir or any of the other ingredients in the tablet. You should also not take this medicine if you have severe liver disease (Child-Pugh Class C), as the drug is primarily metabolised by the liver and could accumulate to dangerous levels in patients with severely impaired hepatic function.

Darunavir Krka must not be taken together with certain medicines that are either potent CYP3A4 inducers (which would reduce darunavir levels to ineffective concentrations) or medicines whose clearance is highly dependent on CYP3A4 and for which elevated plasma concentrations could cause serious or life-threatening events. These include:

• Rifampicin — a powerful CYP3A inducer used for tuberculosis treatment that can reduce darunavir levels by up to 80%
• Oral midazolam and triazolam — risk of excessive and prolonged sedation
• Ergot alkaloids (ergotamine, dihydroergotamine) — risk of acute ergot toxicity including vasospasm
• Cisapride — risk of serious cardiac arrhythmias
• St John's Wort (Hypericum perforatum) — a herbal CYP3A inducer that can dramatically lower darunavir levels
• Lovastatin and simvastatin — risk of severe muscle damage (rhabdomyolysis)
• Sildenafil when used for pulmonary arterial hypertension — risk of sildenafil accumulation

Warnings and Precautions

Talk to your doctor or pharmacist before taking Darunavir Krka if any of the following apply to you:

Liver disease: Darunavir is metabolised by the liver, and cases of drug-induced hepatotoxicity have been reported during post-marketing surveillance, including some fatal outcomes. Patients with pre-existing liver disease, including chronic hepatitis B or C co-infection, are at increased risk. Liver function tests should be performed before starting treatment and monitored at regular intervals thereafter. If signs of liver injury develop (such as dark urine, yellowing of the skin or eyes, nausea, or abdominal pain), treatment should be evaluated immediately.

Skin reactions: During clinical trials and post-marketing use, severe skin reactions have been reported, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS). Although these are rare, they can be life-threatening. Any patient who develops a severe rash, particularly if accompanied by fever, malaise, muscle or joint aches, blisters, mouth sores, or conjunctivitis, should discontinue darunavir immediately and seek urgent medical care.

Sulfonamide allergy: Darunavir contains a sulfonamide moiety. Patients with a known sulfonamide allergy should be monitored carefully, although cross-reactivity has not been definitively established in clinical studies. The structural similarity warrants caution, and any allergic reactions should be taken seriously.

Metabolic effects: Protease inhibitors, including darunavir, have been associated with metabolic disturbances. These can include elevations in total cholesterol, LDL cholesterol, and triglycerides, as well as insulin resistance and hyperglycaemia. Patients should have their lipid levels and blood glucose monitored regularly, particularly those with pre-existing dyslipidaemia or diabetes mellitus. Body fat redistribution (lipodystrophy) may also occur with long-term use.

Haemophilia: Reports of increased bleeding, including spontaneous skin haematomas and haemarthrosis, have been noted in patients with haemophilia type A and B treated with protease inhibitors. In some patients, additional factor VIII was required.

Immune reconstitution inflammatory syndrome (IRIS): When effective antiretroviral therapy is started, patients with severe immune deficiency may develop an inflammatory response to previously dormant opportunistic infections (such as Mycobacterium avium complex, cytomegalovirus, Pneumocystis jirovecii pneumonia, or tuberculosis). This can occur within the first few weeks or months of treatment and may require specific treatment of the opportunistic infection alongside continued antiretroviral therapy.

Pregnancy and Breastfeeding

If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your physician before taking Darunavir Krka. Darunavir may be used during pregnancy when the potential benefit justifies the potential risk. Available human data from the Antiretroviral Pregnancy Registry suggest no increase in the rate of birth defects compared to the general population, although the total number of exposed pregnancies remains limited compared to older antiretrovirals.

Some treatment guidelines, including those from the British HIV Association (BHIVA) and the European AIDS Clinical Society (EACS), include darunavir/ritonavir as an option for pregnant women who require a protease inhibitor-based regimen, particularly for those who are treatment-experienced. Pharmacokinetic studies have shown that darunavir exposure may be reduced during the second and third trimesters, which may necessitate dose adjustment or more frequent viral load monitoring. Your specialist will determine the most appropriate regimen for your individual situation.

HIV-infected mothers are advised not to breastfeed their infants, regardless of antiretroviral treatment, because of the risk of HIV transmission through breast milk. Formula feeding is recommended in settings where safe alternatives to breast milk are available. In resource-limited settings where formula feeding is not safely achievable, WHO guidelines recommend breastfeeding with concurrent maternal antiretroviral therapy to reduce transmission risk.

How Does Darunavir Krka Interact with Other Drugs?

Darunavir is both a substrate and an inhibitor of the cytochrome P450 enzyme CYP3A4. When boosted with ritonavir, it becomes a potent CYP3A4 inhibitor. This means it can significantly increase or decrease the blood levels of many other medicines, and other medicines can also affect darunavir levels.

Drug interactions are one of the most important considerations in HIV treatment. Because patients often take multiple medicines for HIV as well as for other conditions, the potential for clinically significant interactions is substantial. Before starting Darunavir Krka, your doctor should review all your current medications, including prescription drugs, over-the-counter medicines, herbal supplements, and recreational substances.

The following table summarises some of the most clinically important drug interactions. This is not an exhaustive list, and you should always consult your healthcare provider or pharmacist before starting, stopping, or changing any medication while taking Darunavir Krka.

Major Interactions (Contraindicated or Avoid)

Interactions Requiring Dose Adjustment or Monitoring

What Is the Correct Dosage of Darunavir Krka?

The dosage of Darunavir Krka depends on whether the patient is treatment-naive or treatment-experienced, their weight, age, and resistance profile. It must always be taken with food and co-administered with a pharmacokinetic enhancer (ritonavir or cobicistat).

Darunavir must always be taken with food, as food increases the bioavailability of the drug by approximately 30%. Taking darunavir on an empty stomach results in significantly lower blood levels, which may compromise the effectiveness of treatment. The type of food is not critical — a meal or a substantial snack is sufficient.

Adults

The choice between once-daily and twice-daily dosing depends primarily on the presence of darunavir resistance-associated mutations (RAMs). Genotypic resistance testing should be performed before selecting the dosing regimen. If one or more darunavir RAMs are detected (V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V), twice-daily dosing with 600 mg/100 mg ritonavir is recommended.

Children (aged 3 years and older, weighing at least 15 kg)

For paediatric patients, the dose is based on body weight. The 400 mg tablet formulation is generally used for children weighing 40 kg or more. For children weighing between 15 kg and 40 kg, lower-strength formulations or oral suspension may be required, and dosing should follow weight-band-based recommendations as outlined in the product information or local paediatric HIV treatment guidelines.

Paediatric dosing should always be supervised by a physician with experience in treating paediatric HIV infection. Adherence is particularly important in children, as sub-therapeutic drug levels can lead to resistance development.

Elderly

There is limited clinical data on the use of darunavir in patients over 65 years of age. No specific dose adjustment is recommended based on age alone, but elderly patients should be monitored carefully, as they may have a higher incidence of reduced hepatic, renal, or cardiac function, as well as concomitant diseases and other drug therapy.

Missed Dose

If you take Darunavir Krka once daily and you miss a dose by less than 12 hours, take the missed dose with food as soon as you remember, then take the next dose at the usual time. If more than 12 hours have passed since you should have taken it, skip the missed dose and take the next scheduled dose at the normal time with food.

If you take Darunavir Krka twice daily and you miss a dose by less than 6 hours, take the missed dose with food as soon as you remember, then take the next dose at the usual time. If more than 6 hours have passed, skip the missed dose and resume your normal dosing schedule.

Do not take a double dose to make up for a forgotten dose. Consistent adherence to your dosing schedule is essential for maintaining viral suppression and preventing resistance development.

Overdose

There is no specific antidote for darunavir overdose. In the event of overdose, general supportive measures should be employed, including monitoring of vital signs and clinical status. Since darunavir is highly protein-bound, haemodialysis is unlikely to be effective in significantly removing the drug from the body. If overdose is suspected, contact your local poison control centre or emergency services immediately.

What Are the Side Effects of Darunavir Krka?

Like all medicines, Darunavir Krka can cause side effects, although not everybody gets them. The most commonly reported side effects in clinical trials were diarrhoea, nausea, rash, headache, and abdominal pain. Serious but rare side effects include severe skin reactions and hepatotoxicity.

The side effect profile of darunavir has been well characterised through extensive clinical trials involving thousands of patients, including the pivotal ARTEMIS, TITAN, and ODIN studies, as well as post-marketing surveillance data. Side effects are categorised below by frequency according to the standard medical convention used by the EMA.

Long-term metabolic effects deserve particular attention. Studies have shown that protease inhibitor-based regimens can contribute to dyslipidaemia and insulin resistance over time. Patients on long-term therapy should have regular monitoring of fasting lipids, blood glucose, and HbA1c. Cardiovascular risk should be assessed according to standard guidelines, and lifestyle modifications (diet, exercise, smoking cessation) should be encouraged alongside any pharmacological interventions for dyslipidaemia.

Body fat redistribution, also known as lipodystrophy syndrome, has been observed in some patients receiving antiretroviral therapy. This can manifest as increased fat in the abdomen (visceral adiposity), breast enlargement, or fat accumulation at the back of the neck ("buffalo hump"), alongside loss of subcutaneous fat from the face, limbs, and buttocks. The exact mechanism is not fully understood, and it appears to be a class effect of antiretrovirals rather than specific to any single drug.

How Should You Store Darunavir Krka?

Store Darunavir Krka in its original packaging to protect from moisture. No special temperature storage conditions are required, but keep the medicine below 30°C. Keep out of the sight and reach of children.

Darunavir Krka film-coated tablets should be stored in the original blister package or bottle to protect from moisture. The medicine does not require refrigeration and can be stored at room temperature, but should not be exposed to temperatures above 30°C for prolonged periods. Avoid storing the tablets in bathrooms or other humid environments, as moisture can degrade the film coating and potentially affect the drug's stability.

Do not use this medicine after the expiry date printed on the packaging. The expiry date refers to the last day of that month. Once opened, bottles should be used within the period specified on the label. Do not dispose of unused medicines in household waste or down the drain. Ask your pharmacist about proper disposal methods to help protect the environment.

If you travel with Darunavir Krka, keep it in your carry-on luggage in its original packaging. Ensure that you have sufficient supply for the duration of your trip, plus extra doses in case of travel delays. Maintaining uninterrupted antiretroviral therapy is essential for sustained viral suppression.

What Does Darunavir Krka Contain?

Each Darunavir Krka 400 mg film-coated tablet contains 400 mg of the active substance darunavir (as darunavir ethanolate), along with several inactive ingredients (excipients) that are essential for the tablet's structure, stability, and absorption.

Active substance: Each film-coated tablet contains 400 mg darunavir (as darunavir ethanolate).

Tablet core excipients: The inactive ingredients in the tablet core typically include colloidal anhydrous silica, microcrystalline cellulose, crospovidone, and magnesium stearate. These components serve various functions: microcrystalline cellulose acts as a filler and binder, crospovidone is a disintegrant that helps the tablet break apart in the gastrointestinal tract, colloidal silica improves powder flow during manufacturing, and magnesium stearate is a lubricant.

Film-coating: The tablet is coated with a film that typically contains polyvinyl alcohol (partially hydrolysed), titanium dioxide (E171), macrogol, and talc. The film coating serves multiple purposes: it protects the active ingredient from degradation, masks the bitter taste of darunavir, and makes the tablet easier to swallow. The coating may also contain iron oxide pigments that give the tablet its characteristic colour.

Patients with known allergies to any of these excipients should inform their healthcare provider before starting treatment. The product is free from lactose, gluten, and sucrose.